Abstract 240P
Background
Cervical cancer is one of the leading causes of morbidity and mortality among women from cancer of the reproductive organs in developing countries. The purpose of this study is to analyze the dynamics of morbidity and mortality from cervical cancer in the Republic of Kazakhstan.
Methods
Mortality and morbidity rates were calculated for the period 2007-2016. 95% confidence intervals are presented. Incidence of and mortality rates were calculated per 100,000 (0/0000) of female population. All statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) software, version 20.0 for Windows.
Results
For the period from 2007 to 2016, the incidence rates of cervical cancer were analyzed, which varied from 15.24 to 18.83 per 100,000 of female population. Mortality rates tended to decline over the 10-year period under review in 2007, reaching 7.8 to 7.0 per 100,000 of female population in 2016. There is a difference in morbidity and mortality from cervical cancer between different regions of Kazakhstan. An analysis of the distribution of the incidence in the Republic of Kazakhstan revealed the highest incidence rates in the northern region of the country 28.2 (95% CI: 23.6-33.5) and the north-eastern region 27.3 (95% CI: 22.4-32.9) per 100,000 of female population. On the other hand, the lowest morbidity and mortality rates were found in the southern region substituted 10.4 (95% CI: 7.4-14.2) and 5.4 (95% CI: 4.3-6.8) per 100,000 of female population respectively.
Conclusions
Thus, the incidence of cervical cancer in the Republic of Kazakhstan has increased over the 10-year period in question, while mortality rates have been gradually decreasing. Such trends can result from the national screening program which was implemented in Kazakhstan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract